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Background: Until now, the major prognostic factors for pediatric acute lymphoblastic leukemia (ALL), age, white
blood cell count and chromosomal alterations are initially taken into account for the risk stratification of patients.
In the light of protein marker studies to classify subtypes of Acute Myeloblastic Leukemia efficiently, we have
compared the lymphoblastes proteome in Childhood ALL in accordance with the presence of t(12;21), indicator of
good prognosis, usually.
Methods: Protein expression in pre-B2 lymphoblastic cells, collected from residual bone marrow cells after diagnostic
procedures, was analyzed using two dimensional gel electrophoresis protocol. Protein spots whose average normalized
volumes were statistically different in the two patients groups (n = 13; student t test p < 0.01), were excised. Tryptic
peptides were then analyzed using a nano-LC1200 system coupled to a 6340 Ion Trap mass spectrometer equipped
with a HPLC-chip cube interface. The tandem mass spectrometry peak lists extracted using the
DataAnalysis program, were compared with the protein database Mascot Daemon.
Results: We focused on twelve spots corresponding to sixteen identified candidate proteins among the 26 found
differentially expressed (p≤ 0.05) regarding the presence of t(12;21). Among over expressed proteins, two proteins
were implicated in cellular growth arrest (i.e. calponine 2, p≤ 0.001 and phosphatidylinositol transfer protein beta,
p≤ 0.001) in accordance with good prognosis, while two other proteins favored cell cycle proliferation (i.e. methionine
adenosyl transferase 2β, p≤ 0.005 and heterogeneous nuclear ribonucleo-proteins A2 p≤ 0.01) and could therefore
be good marker candidates of aggressiveness. Level of expression of proteasome subunit beta type-2 (p≤ 0.01) and
protein casein kinase 2α (p≤ 0.01) which both favored apoptosis, deubiquitinating enzyme OTUB1 (p≤ 0.05)
and MLL septin-like fusion protein MSF-B, septin 9 i4 (p≤ 0.01) were in accord with a good prognosis related
to t(12;21) lymphoblasts.
Conclusion: By drawing up the protein map of leukemic cells, these new data identified marker candidates of
leukemic aggressiveness and new t(12;21) patients subgroups. These preliminary results will be in the near future
confirmed by using a larger sample of pre-B2 childhood ALLs from national lymphoblastic cell collections.
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The most common form of childhood cancer is the
acute lymphoblastic leukemia (ALL), representing up to
30% of childhood cancers. The major prognostic factors,
age and white blood cell count, are initially taken into
account for the risk stratification of patients. Recurrent
chromosomal alterations detectable by karyotyping,
fluorescence in situ hybridization (FISH), or molecular
techniques are found in 75% of childhood ALL and have
important implications on prognosis [1]. The chromo-
somal rearrangement t(12;21) ETV6-RUNX1 is associ-
ated with favorable outcome in B-ALL and much more
frequent in childhood ALL (25% of B lineage ALL) [2].
The identification of genomic alterations is currently
transforming our understanding of the genetic basis of
leukemogenesis. Among these new genetic factors, alter-
ations of the lymphoid transcription factor IKAROS
(IKZF1) in B-ALL are remarkably associated with a poor
outcome [3]. Though it is not the only example, only
few other genetic alterations can be clearly associated
with outcome in childhood ALL. This new insight on
genomic profile of childhood ALL still has to be further
explored. In the light of studies in which identified pro-
teins, differentially expressed, could serve as markers to
classify M1 and M2 subtypes of Acute Myeloblastic
Leukemia, a correlation was also found between the ac-
cumulation of some proteins and therapeutic outcome
and relapse time of the disease [4,5].
The present work relies on the global analysis of the
protein expression of lymphoblastic cells and the identi-
fication of proteins as new biological markers, related to
cytogenetic abnormalities. Therefore, we compared the
whole proteome of bone marrow lymphoblasts collected
by bone marrow aspiration during the diagnosis proced-
ure. The proteome of each bone marrow lymphoblasts
sample from pre-B2 t(12;21) ALLs, has been mapped
using two dimensional poly acrylamide gel electrophor-
esis (2 DE) and compared to those from pre B2 ALLs
without that translocation.
We identified twelve spots (corresponding to sixteen
candidate proteins) whose average level was highly corre-
lated either with the presence or the absence of t(12;21)
EV6-RUNX1 detected by cytogenetic analysis. Among the
identified proteins two of them, protein kinase 2α (CK2α)
and septin 9 i4 (v4) (SEPT9), are related to genes already
identified and described in leukemogenesis, i.e. IKAROS
and MLL, respectively [3]. CK2α is implicated in the phos-
phorylation of several proteins like phosphatase and tensin
homolog (PTEN) and Ikaros acting on leukemia cell sur-
vival [6,7]. SEPT9 is implicated in cytokinesis and its role
in tumorigenesis has been shown in various human tu-
mors [8]. Beside these two proteins of interest we found
other significantly differential amount of proteins related
in some way to cell survival and already pointed out inseveral solid tumors. They could be related to several
genes or pathways in relation with the regulation of the
cell cycle, the apoptosis and also to the energetic metabol-
ism of these very proliferative leukemic cells. Discussion
debates about which protein might be a marker of good
versus bad prognosis and which protein could be explored
as a treatment target to defeat leukemogenesis.
Results
Patients
Among the thirteen patients (Table 1) with newly diag-
nosed B-ALL (pre-B2) which were included in this study,
six children had an identified t(12;21) with an ETV6-
RUNX1 fusion transcript. The global outcome was good
for both groups, 5/6 in the translocation group being
alive in first complete remission (CR1) with a median
follow-up, of 82 months (range 72–129), 6/7 were in
CR1 in the group without t(12;21) (median follow-up
102.5 months; range 75–141). For both dead patients,
death was directly related to the recurrence of ALL.
Protein identifications
A total of 4000 spots were detected on 2-DE maps
(Figure 1). Protein maps were gathered with regard to
the presence (n = 6) or the absence (n = 7) of t(12;21)
(Table 1). Twenty six spots were found differently expressed
in the two groups of patients (Table 2 for the top 12 spots;
the whole spot informations can be seen in Online
Additional file 1: Table S1) (student-t test, p ≤ 0.05). Re-
peatability assay was performed as indicated in Patients,
material and methods, giving reliable results (see On-
line Additional file 1: Figure S1). Most of these proteins
are involved in the cell cycle regulation (25%), metabol-
ism (32%) and apoptosis (14%) (Figure 2A). The last
ones (18%) are implicated in cytoskeleton organization,
protein elongation or posttranslational events while 11%
are not yet identified. However, among the 26 differen-
tially expressed spots, only eleven spots (Figure 1A, see
also Online Additional file 1: Figure S2 which located
the last 15 spots), representing fifteen candidate proteins,
were expressed with a sufficient reliable statistic power
(student-t test, p ≤ 0.01, with a Power higher than 80%) in
the two groups of patients (Figure 3). The average normal-
ized volumes values and statistic ranks are listed Table 2.
Five of them were expressed mostly in t(12;21) ALLs. The
last seven spots were expressed mostly in the absence of
this translocation. Corresponding proteins (Table 2, and
Online Additional file 1: Table S1), identified by Mass
Spectrometry with relevant Mascot score (more than 3
ions scores > 48) (see Online Additional file 1: Figure S3)
were of great interest in terms of leukemogenesis since in-
volved in mechanisms related to either the cell cycle regu-
lation, or apoptosis, or energetic metabolism (i.e., 43%,
29% or 28% of them, respectively) (Figure 2B). Principal
Table 1 Clinical and biological status of childhood pre-B2 ALL patients
Group of ALL patients Patients ID Age at diagnosis (Months) Peripheral bloodlymphocytes (Giga/L) Karyotype Fusion transcripts Outcome
With t(12; 21)
BACYO 24 48,7 t(12; 21) ETV6/RUNX1 CR1
GUEKE 118 42,2 t(12; 21) ETV6/RUNX1 CR1
LECRO 76 5,4 t(12; 21) ETV6/RUNX1 CR1
MARLE 42 166 t(12; 21) ETV6/RUNX1 CR1
PELAD 50 20 t(12; 21) ETV6/RUNX1 Dead*
RIFEM 76 216 t(12; 21) ETV6/RUNX1 CR1
Other karyotype abnormalities
BOILE 18 2,8 dic(9;20) NA CR1
CREBA 180 11,6 mono 21 NA CR1
DESNA 13 15,5 rear9p NA CR1
JUGEL 34 8,5 Hyperploidy NA CR1
LEMAL 48 56 t(9; 22) BCL/ABL1 CR1
MORLU 171 171 t(9; 22) BCL/ABL1 Dead*
ROSLO 57 6,1 Hyperploidy NA CR1
The bold numbers indicates values higher the threshold of FRALLE 2000 protocol. CR1 = First complete remission; dic = dicentric; ID = Identification; mono =monosomy;
NA =Not applicable; rear = Rearrangement. * = Directly related to the recurrence of ALL.
Figure 1 Differential expression of proteins in bone marrow lymphoblastic cells from childhood pre-B ALL. – A – Down: Two-DE gel
image of lymphoblastic cells proteins issuing from bone marrow. Numbers refer to the top eleven proteins which have been characterized and
listed in Table 1b. Up: Magnification view of interesting zone – B – 3 D montage of the three top differentially expressed spot proteins (i.e., 2-DE
Batch 2768, 3185 and 4083 on rank 1, 2 and 3, respectively). Only 2 individual spot images in each group (1 and 2 = Pre-B2 ALL with t(12;21),
1′ and 2′ = Pre-B2 ALL with other karyotype abnormalities) are shown.
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Fold changes/ALL t(12;21) versus others
(average normalized volume +/− SD) 105
Group with the upper
average volume
Student -t test Power (after
q value)
1 (2768) CNN2 gi/49456619/ Q99439 1.9/(38.59 +/− 8.1 vs 20.76 +/− 4) Pre - B2, t(12;21) p ≤ 0.001 0.998
2 (3185) CDSα gi/32307132/ Q9Y697-1 2.2/(9.5 +/− 3.8 vs 20.98 +/− 5.2) Other Pre - B2 p ≤ 0.001 0.985
3 (4083) PITPβ gi/6912594/ P48739 2/(12.8 +/− 3.1 vs 6.28 +/− 2.21) Pre - B2, t(12;21) p ≤ 0.001 0.983
4 (2457) hnRNP-E1 gi/460771/ Q15365 1.4/(29.87 +/− 4.69 vs 41.57 +/− 4.88) Other Pre -B2 p ≤ 0.005 0.976
BUB3α gi/4757880/ O43684
5 (4069) PDH-E1 gi/149242791/ P13804 -1 1.5/(15.16 +/− 4.33 vs 23.29 +/− 3.12) Other Pre -B2 p ≤ 0.005 0.955
6 (2090) MAT2β i1 gi/11034825/ Q9NZL9 1.5/(21.94 +/− 3.89 vs 15.06 +/− 2.91) Pre - B2, t(12;21) p ≤ 0.005 0.915
7 (2800) PSMB2 gi/4506195/ B7Z478 1.7/(9.48 +/− 2.49 vs 5.69 +/− 1.63) Pre - B2, t(12;21) p ≤ 0.01 0.878
8 (4081) CECR5 gi/14861834/ Q9BXW7 1.3/(28.51 +/− 4.48 vs 37.3 +/− 4.81) Other Pre - B2 p ≤ 0.01 0.867
BUB3α gi/4757880/ O43684
9 (3121) CK2α gi/4503095/ P68400 1.5/(13.55 +/− 2.36 vs 20.31 +/− 4.9) Other Pre - B2 p ≤ 0.01 0.864
SEPT9 i3 gi/668381/ Q9UHD8-3
10 (2056) HnRNPA2 gi/4504447/ P22626-2 2/(18.28 +/− 6.56 vs 9.26 +/− 4.77) Pre - B2, t(12;21) p ≤ 0.01 0.854
11 (3120) IVAD gi/3212539/ P26440 1.5/(14.98 +/− 3.44 vs 22.64 +/− 5.34) Other Pre B2 p ≤ 0.01 0.835
FBA gi/312137/ P05062
PSMB6 gi/1526426/ P62333
12 (2656) OTUB1 gi/6841176/ Q96FW1 1.8/(58.54 +/− 19.8 vs (32.01 +/− 14.53) Pre - B2, t(12;21) p ≤ 0.05 0.787
Two-dimensional gel electrophoresis (2-DE) Batches are located Figure 1A (in case of the top eleven) and Additional file 1: Figure S2 (for the following 15th). In column’ protein names, R1, R2 and R3 are the Mascot
rank based on the whole ionic scores detected (upper or equal to 48). Power analysis is performed independently for each spot, taking into consideration the sample size and variance expression value (Progenesis
SameSpots V4). CNN2 = calponin-2; CDSα = cysteine desulfurase, mitochondrial isoform a; PITPβ = phosphatidyl- inositol transfer protein beta isoform; BUB3a = mitotic checkpoint protein BUB3 isoform a; PDH E1 =
chain A, pyruvate dehydrogenase E1 S264e Variant; MAT2β = methionine adenosyl transferase 2, subunit beta, isoform 1; PSMB2 = proteasome subunit beta type-2, isoform 1; CECR5 = cat eye syndrome critical region
protein 5 isoform 2; CK2α = casein kinase II subunit alpha isoform a; SEPT9_i3 = MLL septin-like fusion protein MSF-B; hnRNPA2 = heterogeneous nuclear ribonucleo- proteins A2; IVAD = Chain A, isovaleryl-Coa

















Figure 2 Pie chart representing the principal protein’s
functions with differential expression in lymphoblasts from
pre-B2 ALL children, depending on the presence or absence of
the translocation t(12; 21). Proteins are characterized by LC-MSMS
and Mascot score from 2-DE spots with: A- Differential expression
with p ≤ 0.05 (n = 28); B- Differential expression with p≤ 0.01
(n = 15). ND = none defined.
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methods) indicated that the amount of all the 26 spots of
interest, when gathered together, could discriminate 2
groups of patient, correlating with the presence or absence
of t(12;21) (Figure 4A,B).
Among the proteins involved in cell cycle regula-
tion, are the calponin-2 (CNN2) and methionine ade-
nosyltransferase 2beta (MAT2β) variant 1, which are
highly expressed in ALL with t(12;21), usually associatedFigure 3 Histogram of the average normalized volumes of the top ele
from pre-B2 ALL children, depending on the presence or absence of
Pre-B2 ALLs with other karyotype abnormalities, n = 7. p ≤ 0.001***; p ≤ 0.00
in Table 2.to good prognosis (p < 0.001, with a power of 0.998;
p < 0.005, with a power of 0.985, respectively) (see Table 2).
On the contrary hnRNP-E1, mitotic checkpoint protein
BUB3α (or BUB3α) or MLL septin-like fusion protein
MSF-B (SEPT9_i4) were weakly expressed in ALL with
t(12;21), (p < 0.005).
Among proteins involved in apoptosis, phosphatidylinositol
transfer proteins beta (PITPβ) was highly expressed in
ALL with t(12;21), while the casein kinase 2 alpha (CK2α)
protein was weakly expressed in this group of patients
(p < 0.001 and p < 0.01, respectively). Proteasome subunit
beta 2 (PSMB2), one of the two proteins of the PSM
which we found, was predominant in ALL with t(12;21)
(p < 0.01) while PSM beta 6 (or P42 i.e., PSMB6) predomi-
nated in the other group of pre-B2 ALL (p < 0.01). Inter-
estingly, HSPC263 (i.e., OTUB1), a deubiquitinating
enzyme was slightly over expressed in t(12;21) ALLs, in
the rank just after the first group of eleven spots described
(Table 2).
The other proteins which were implicated in cellular
metabolic pathways (i.e., cystein desulfurase alpha (CDSα),
pyruvate deshydrogenase E1 (PDH-E1), cat eye syndrome
critical region protein 5 (CECR5), isovaleryl CoA deshy-
drogenase (IVAD) and fructose biphosphate aldolase
(FBA)) were all together predominant in the group of
pre-B2 ALL without t(12;21) (p < 0.005, p < 0.005, p < 0.01,
p < 0.01, p < 0.01, respectively). CECR5 has not yet been
described in lymphoblasts.ven spots of protein with differential expression in lymphoblasts
the translocation t(12;21). ∎ = Pre-B2 ALLs with t(12;21), n = 6; □ =
5**; p ≤ 0.01*. Numbers are protein arranged by statistical rank, listed
Figure 4 Principal components analysis of spots with differential expression (student t test, t < 0.01), in lymphoblasts from pre-B2 ALL
children, depending on the presence or absence of the translocation t(12; 21). Results were obtained with Progenesis SameSpotsV4. Left
dotes (∎) are t(12;21) pre B2 ALLs patients (n = 6); Right dotes (▲) are other karyotype abnormalities in pre B2 ALLs patients (n = 7) (see
comments below). A/ Spots differentially expressed with student t test value: p > 0.01 and p≤ 0.05 (n = 15); B/ Spots differentially expressed with
p ≤ 0.01(n = 11). Names close to dotes are identification badge of patients listed in Table 1.
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Little is known about proteomic profiling in childhood
ALL. Recently, protein expression was compared in
leukemia cell lines and in patients before (i.e., at the
diagnostic day) and after 7 days (D8) of prednisolone
treatment [9]. The results focused on two proteins dif-
ferentially expressed: the proliferating cell nuclear anti-
gen, which plays important roles during DNA
replication and repair and the voltage-dependent anion
channel which participates in the formation of the per-
meability transition pore complex, are responsible for
the release of mitochondrial products that trigger apop-
tosis [10]. All these data confirmed the interest of prote-
omics in hematology malignancy.
The aim of the present work was to identify proteins
that could be related to a good prognosis, often associ-
ated to the translocation t(12;21) in childhood ALL.
Thus, we pointed out differences in amounts of some
proteins expressed in t(12;21) ALLs and non t(12;21)
ALLs. These proteins have been classified regarding
their biological activity. We discussed the relevance of
these proteins as diagnostic markers and/or targets for
leukemia therapy.Proteins involved in cell cycle regulation
Some proteins of this group are involved in the cell cycle
regulation (e.g. CNN2 the neutral isoform which belongs
to a family of actin filament-associated proteins). CNN2
has been shown to inhibit cell proliferation, suggesting
its regulatory role in cytokinetic activities [11]. CNN2 is
also known to activate PKC phosphorylation, a key
mechanism that mediates growth arrest in tumor cell
lines [12]. Its increased or reduced expression has been
associated in solid tumors with good or poor prognosis,
respectively [13]. So, the over expression of CNN2 here
observed in t(12;21) ALLs, could reduce the cell prolifera-
tion and could be related to the good prognosis usually
associated to this translocation (Table 3).
The MAT2β subunit is the second protein of this
group. It was found over expressed in t(12;21) ALLs.
MAT2 is implicated in the methylation protein pathway
(i.e. trans-methylation, trans-sulfuration, and polyamine
synthesis) and acts as a transcriptional co-repressor of
the oncogene MafK [14,15]. Accordingly, MAT2 activity
is constitutively expressed in stimulated and actively
dividing T cells, as well as T leukemic cells [16]. The
subunit MAT2β, which is catalytically inactive, is
Table 3 Concluding remarks and future directions
Expression observed in t(12;21) ALLs Major expected cellular effects Comments Future directions
Over expression of CNN2 Mediates cellular growth arrest In favor of good prognosis associated to t(12;21) Is CNN2 a marker of good prognosis? It has to be
confirmed with a largest group of patients
Over expression of MAT-2β Favors the cell proliferation with anti-
apoptotic effect
Would be a marker of cancer aggressiveness Would be explore as a target of chemotherapy
Over expression of hnRNPA2 Favors the cell proliferation Would be a marker of cancer aggressiveness Would be explore as a target of chemotherapy
Over expression of PITPβ Slow down the cell proliferation Is it a marker of good prognosis? Exploration of the balance PITPα/β
Under expression of BUB3 Avoid slippage of mitosis Over expression in non t(12;21) could lead to hypo/
hyperpolyploid cells
Mitoses analysis
Under expression of hnRNPE2 Favors apoptosis In favor of good prognosis associated to t(12;21) Exploration of the balance between hnRNPE2, PSMB2
and PSMB6 and/or checkup the apoptosis pathways
Over expression of PSMB2 Favors apoptosis
Under expression of PSMB6 Hinders apoptosis In favor of leukogenesis
Under expression of CK2α Slow down the proliferation by
apoptotic effect
In favor of good prognosis associated to t(12;21) Both expressions in combination with Ikaros (Ikzf1)
phosphorylation and degradation ought to be
clarified precisely
Over expression of HSPC263(OTUB1) Favors deubiquitination Does it prevent Ikaros (Ikzf1) degradation?
Under expression of metabolism pathway
proteins (i.e., CDSα; CECR5; PDH; IVAD; IDH;
Electron transfer flavoprotein)
Sign the level of energetic consumption In favor of good prognosis associated to t(12;21) Checkup lymphoblasts metabolism pathway: High
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pression of MAT2β is successfully silenced, excessive
apoptosis and growth slowdown is observed in Jurkat
leukemic T cell [17,18]. Recently MAT2β v1 (here char-
acterized), has been identified as an anti-apoptotic com-
ponent through Sirtuin 1 signaling [19]. Therefore, the
over expression of MAT2β in t(12;21) ALLs cannot be
considered as a good prognostic factor. It seems to have
the opposite effect on cell proliferation when compared to
CNN2. MAT-2β has to be evaluated as a possible target
to improve prognosis in the t(12;21) ALLs (Table 3).
HnRNPA2 functions as telomeric capping factor protect-
ing telomeric DNA in vivo against nuclease digestion by
recruiting the essential RNA subunit (hTR) to the telomere
[20]. RNAi, reduction of hnRNPA1 and hnRNPA2 signifi-
cantly reduced the proliferation rate of Colo 16 cells, sug-
gesting that these hnRNP members may be classified as
oncogenes [21]. HnRNPA2 is found overexpressed in t(12,21)
ALLs and thus would contribute to favor the pre - B2 prolif-
eration and would be a marker of leukemogenesis (Table 3).
The three last proteins included in this group (i.e.
hnRNP-E1, BUB3α and SEPT9_i4) are under expressed
in t(12;21) ALLs.
HnRNPE1 is a member of the RNA binding protein fam-
ily which includes important mitotic regulators and effec-
tors, having multiple functions in hematopoietic cells. It is
involved in controlling stem cell proliferation and differen-
tiation [21,22]. Particularly, acting as “chaperone” molecule
on the RNA, hnRNPs E1 functions as crucial modulator
of mRNA stability, and translation in hematopoietic
cell differentiation [23]. It stimulates the translation of
c-myc and Bag-1, having an anti-apoptotic effect on
cancer cells [21,24]. The accumulation of hnRNPE1 in
lymphoblastes could induce an anti-apoptotic effect,
worsening the disease. The under expression of hnRNPE2
observed in t(12;21) ALLs would contribute to apoptosis in
these leukemic cells (Table 3).
The BUB3α is one of the components of the spindle as-
sembly checkpoint (SAC) which interacts with BUB1 and
leads to delay the cell cycle progression [25]. However, in
conditions where the SAC is kept active, some cells escape
from mitosis, resulting in polyploid cells [25]. Its over ex-
pression in non t(12;21) ALLs could contribute to the slip-
page of mitosis toward a hypo/polyploid cells (Table 3).
SEPT9_i4 is an isoform of the GTP binding septin
family, involved in cytokinesis. Over expression of the
short isoform SEPT9_i4 disturbs septin interactions and
cellular motility which can be related to neoplasic asso-
ciated phenotypes [26]. SEPT9_i4 over expressing cells
have enhanced survival in the presence of clinically rele-
vant microtubule acting drugs. Its over expression in
several cancers may be clinically relevant with a contri-
bution of drug resistance forms of cancer [27]. This i4
variant is the COOH terminal sequence of all theisoformes [28]. Thereby it may be difficult to reach it as
a specific target. By introducing mutations that prevent
SEPT9 self - association at the N- and C-termini, it has
been shown that septin filament disruption causes de-
fects in the late stages of cell division before abscission,
similar to these observed upon SEPT9 depletion [28].
Proteins involved in apoptosis
Among proteins which are principally implicated in apop-
totic pathways and may have a prognostic value (i.e.,
PITPβ, CK2α, and PSMB2, PSMB6), phosphatidylinositol
transfer proteins beta (PITPβ) and CK2α have an impact
on Pl3K pathway.
PITPβ was highly expressed in the group of t(12; 21)
ALLs. Physiologically, PITPβ is poorly expressed and fa-
vors the activation of a golgian PI3K [29]. PITPβ accu-
mulation, by modifying the balance PITPα/β, induces a
decrease of proliferation and an increase of apoptosis
[30]. The exploration of the balance PITPα/β in ALLs
may be a useful biological marker.
On the contrary, CK2α was under expressed in t(12;
21) ALLs. CK2α disturbs the PI3K pathway by phos-
phorylating PTEN and AKT, thereby favoring cell prolif-
eration by an anti-apoptotic effect [7,31]. The over
expression of CK2α has been shown to increase the deg-
radation of Ikaros protein (i.e., a tumor suppressor in
ALL) via the ubiquitin pathway [3,32,33]. Interestingly
in the t(12, 21)ALLs, not only CK2α is under expressed
but OTUB1, a deubiquitinating enzyme, is found slightly
over expressed (see Table 2, rank 12) [34]. OTUB1
hydrolase can specifically remove ‘Lys-48”-linked conju-
gated ubiquitin from proteins and plays an important
regulatory role at the level of protein turnover by pre-
venting degradation. It has recently been identified as a
novel p53 regulator [35]. All together this could result in
an preservation of Ikaros functions and would contribute
to the good prognostic claimed for t(12;21) ALLs.
The two other proteins implicated in apoptosis (i.e.,
PSMB2 and PSMB6) are constitutive of the proteasome.
The proteasome is responsible for the degradation of
intracellular proteins involved in cell cycle control and
regulation of apoptosis, including the tumor suppressor
protein p53 and specific cyclin dependent kinases [36]. At
this time we cannot explain why PSMB2 is predominant
in t(12;21) ALLs, while PSMB6 is weakly expressed. New
therapies against tumor growth and development have an
anti-ubiquitin-proteasome pathway effect [36].
Two pathways in which most of these proteins (i.e., in-
volved in apoptosis and also BUB3) were pointed out with
Protein Center Software (Thermo Scientific ProteinCenter
Software). The first one (Raw p-value, p < 6.98 10−7 and
false discovery date (FDR), p < 5.41 10−4) is the negative
regulation of protein ubiquitination (i.e., BUB3, OTUB1,
PSMB6 and PSMB2). The second one (Raw p-value: p <
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of mitotic cell cycle phase transition (i.e., BUB3, CK2a,
PSMB6 and PSMB2). Both of them involved the same
proteins. However, OTUB1 and CK2α exhibit an opposite
effect on ubiquitination, CK2 acting indirectly on cell
cycle progression.
Proteins involved in metabolic pathway
Proteins of the third group implicated in metabolic path-
way (i.e., CDSα, PDH-E1, IVAD and FBA) are predomin-
ant in pre B2 ALLs without t(12; 21). CDS, the second
protein at the statistical average rank, is involved in cel-
lular iron homeostasis and in the production of seleno-
proteins which have antioxidant functions and possibly
cancer-protective effects [37]. IVAD and FBA are in-
volved in glucose metabolism [38]. FBA participates to
ATP synthesis in the glycolytic glycol pathway in cancer
cells [39]. Interestingly, increased glycolytic rate in ALL
is directly related to glucocorticoid resistance in primary
leukemic cells of pediatric ALL patients [40]. The simi-
larity of CECR5 to yeast phosphatidyl synthases suggests
that it is an enzyme involved in fatty acid metabolism,
possibly in the production/processing of membrane
phospholipids [41]. Its implication in ALLs has to be ex-
plored (Table 3).
Conclusion and future directions
Through this protein profile of children with or without t
(12;21), several proteins of interest emerge, defining a
“protein-map” associated to some subgroups of patients
with particular features. The correlation between the pro-
teins expression and the t(12;21) or its fusion transcript
ETV6-RUNX1 still has to be confirmed. Nevertheless, this
new approach for identification and classification of pa-
tient subgroups could lead to interesting therapeutic
target. At the fundamental level, the identification of
the biological pathway regulated by RUNX1 is also of
importance to define the role of these proteins in
leukemogenesis. Indeed, this is well documented for the
fusion transcripts but rare or inexistent at the level of pro-
teins translation or modulation [42]. Altogether, this
proteomic analysis focuses on major proteins (Table 3)
playing important roles in leukemogenesis. At the present
time, the difficulty is to conclude on the order of import-
ance of the expression of each protein implication in the
same way (i.e. cellular proliferation or apoptosis). All lym-
phoblasts studied are coming from ALLs and so are
leukemic cells. Consequently, it is not conflicting to find
CNN2 and PITPB over expressed, put on the brake of
cell growth and while MAT-2β or HnRPA2 also over
expressed in t(12, 21) ALLs speed up the cell cycle. Future
work will be devoted to study a larger panel of patients,
and to confirm the proteins CNN2, protein CK2α and
OTUB1 as good candidates markers of prognosis and ifthe some other proteins could be targeted by chemother-
apy. The monitoring of the amount of these proteins fol-
lowing the induction treatment could also indicate its
signaling pathway efficiency [43]. At the same time, the
metabolism pathway check-up would inform on the level
of energetic consumption linked to cancer aggressiveness.
Another interesting question concerns the impact of
the expression of CK2α [6,7] and, possibly, OTUB1, on
degrading Ikaros. Different ways of CK2 inhibition by
small-molecule inhibitors have already been suggested as
therapeutic tools for several cancers [44]. CK2 acts on
Pl3K pathway by phosphorylating PTEN thereby leading
to leukemia cell survival. It would be interesting to test
in vitro inhibitors of CK2 and to compare their effect to
inhibitors targeting PI3K/PKB [45]. Modulators or activa-
tors of OTUB1 would be also useful tools to control the
ubiquitination/deubiquitination of proteins which slow
down leukemogenesis (i.e., Ikaros, particularly) [46].
Patients, material and methods
Patients
Thirteen children with newly diagnosed B-ALL are in-
cluded in this study. Analyses were carried out on residual
bone marrow cells (BMC) after diagnostic procedures, in
agreement with the requirements of the ethical committee
of the Rouen University Hospital and the French ethical
laws [47]. All patients were included in the French proto-
col for childhood ALL (FRALLE 2000) [48]. Patients were
classified in two different groups according to the pres-
ence or absence of a translocation t(12; 21).
Cytogenetic and molecular analysis
Chromosome and FISH analysis were performed on un-
stimulated bone marrow and/or peripheral blood cells
cultures using EV6-RUNX1 Abbott dual color DNA
probes. EV6-RUNX1 fusion gene transcript is studied by
real time –polymerase chain reaction as described in
Biomed −1 concerted action’s report [49].
Cell preparation
Leukaemia cells from BMC were isolated by Ficoll-
Hypaque (Eurobio, Les Ulis, France) density gradient
centrifugation and stored at −80°C [50]. A Human pre-
B-ALL line, Nalm 6, was grown as indicated by DSMZ.
(DSMZ, Braunschweig).
Two-dimensional electrophoresis (2-DE) of proteins
Proteins were extracted from dounce homogeneized cell
pellets double washed in RPMI 1640, according to the
protocol of the 2-D Clean-Up kit (GE Healthcare). The
isoelectric focusing was performed by using dried 18-cm
Immobiline pH 3–11NL (IPG) Strip rehydrated with
20 mM DeStreack IPG buffer pH 3–11, (GE Healthcare).
Fifty μg of protein samples (or 300 μg for preparative 2-
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were focused using Ettan IPGphor 3 (pI 3–11 program).
After equilibration, strips were sealed on the top of poly-
acrylamide gel cassette precasted with the automate 2D
Optimizer (Nextgen) (i.e. Sigmoid curve 6% to 18% gra-
dient of Acrylamide-bis Acrylamide (37.5:1). 2-DE was
carried out (500 V, 40 mA, 4 Hrs) in Ettan Dalt six Large
Vertical System as described previously [51].
Gel staining and image analysis
Analytical Gels were silver stained using PlusOne Staining
kit, protein (GE Healthcare Lifescience) based on a simpli-
fied method. For preparative scale, the gels were stained
by colloidal Coomassie blue G-250 (Sigma Chemical Co).
After coloration, gels were scanned and quantified by
computing scanning densitometry (ImagScanner III
densitometer-GE Healthcare). A total of 4000 protein
spots were discriminated on 2-DE (i.e., whose the volume
was up than 300,000). All gel images were normalized to
the total valid spot volume of each gel and included for
statistical group matches as described below.
Global statistical analysis
Statistical analysis was carried out with Progenesis
SameSpotsV4 [52]. Before “Progenesis software” ana-
lysis, the first step of analysis was to check the repeat-
ability of our analysis by comparing randomly spots
average volume in three gels per patient (see Additional
file 1: Figure S1A). We indeed observed that artifactual
results could be obtained when superposition of too
many gels (each of them exhibiting about 4000 spots)
was performed in the same analysis. That is the reason
why in the next step, one representative of the three gels
per patients was selected for gel images alignment (see
Additional file 1: Figure S1B). Then statistic analysis has
been performed with “Progenesis software” and the re-
sults are represented Figure 3, pointing out the eleven
spots of the main area (seen in Figure 1). In the last step,
we returned on our analysis, pointed out these eleven
spots of the main area and compared the three protein
maps for each thirteen patients (see Additional file 1:
Figure S1B).
Gel spots whose intensity change was greater than
30% (student t test; p < 0.01) and exhibiting a power
higher than 0.8 were claimed statistically relevant (Pro-
genesis SameSpots V4). Therefore, multivariable statis-
tical analysis was performed on data matrix of 15/or 12
rows (i.e., spots proteins; Figure 4A and B, respectively)
and 2 columns (patients with t(12;21) and other pa-
tients). Automatic correlation and hierarchical clustering
of protein spot intensities and Principal component ana-
lysis (PCA) was applied, using Progenesis Samespots
software, to analyse the similarity of protein patterns
among gels and the expression profiles of protein spotsfulfilling the above criteria. PCA of raw data (i.e., spot vol-
ume values, average over 13 patients) allowed to discrim-
inate two Principal Components (PC1 and PC2) which
together explained 67.9% or 74.65% of the variance
(Figure 4A and B, respectively). The PC1 accounted for up
to 67.9% of the variance and was related to the diagnostic,
each being distributed along PC1.Mass spectrometry identification
Spots of interest were excised and trypsin digestion was
performed as previously described [51]. Peptide were
then analyzed using a nano-LC1200 system coupled to a
6340 Ion Trap mass spectrometer equipped with a
HPLC-chip cube interface (Agilent Technologies, Massy,
France). The tandem mass spectrometry peak lists were
extracted using the DataAnalysis program (version 3.4,
Bruker Daltonic) and compared with the protein data-
base using Mascot Daemon (version 2.1.3). The deter-
mination of at least three peptide sequences with a
Mascot Ion Score over 48 allowed a satisfactory identifi-
cation of the protein.Additional file
Additional file 1: Table S1. Classification of differentially expressed
proteins in pre-B2 lymphoblastic cells from children with ALL. 2-DE
Batches are located Figure 1b. R1, R2 and R3 (In protein names column)
are the Mascot rank basis on the whole ionic scores (IS) detected (Here
only IS, listed in Additional file 1: Figure S3, upper or equal to 48 are
taken in consideration); Power analysis was performed independently
for each spot, taking into consideration the sample size and variance
expression value (Progenesis SameSpots V4). Figure S1. Normalized
volume of silver stained spots from two dimensional gels: A- Average
normalized volume realized from 9 patients which were chosen ran-
domly. Gels were performed in triplicate (bars: SD, n=3). Spot A to spot L
were chosen randomly to valid the method. B- Normalized volume
realized from 13 patients included in final statistical analysis (referred in
the main manuscript Figure 3), focusing on the 11 first spots discussed
in the main document. Values of three 2D maps for each ALL patients
with t(12;21) (Ba), or ALL patients without this translocation (Bb).
Figure S2. Spot localization on 2-DE gels: Only spots submitted with
success to the student t test values (p>0.01 and p≤ 0.05) are numbered.
Numbers correspond to protein spots listed in Table 2. Figure S3. Mascot
research results for the first eleven spot proteins ordered by statistic rank
(Progenesis SameSpotsV4 software –see Additional file 1: Table S1). For each
identified trypsic peptide, individual ions scores up to 48 indicate identity or
extensive homology (p<0.05). Matched peptides are shown in bold red.
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